4 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
14 Nov 23
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
4:26pm
targeted extracellular protein degradation platform; several targets using second and third generation technologies expected to yield sustainable pipeline
8-K
EX-99.1
BHVN
Biohaven Ltd.
31 Jul 23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
4:29pm
-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track
8-K
EX-99.1
BHVN
Biohaven Ltd.
28 Jul 23
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
4:35pm
a deep pipeline of partially derisked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable
10-12B
EX-10.7
BHVN
Biohaven Ltd.
10 Aug 22
Registration of securities
5:07pm
management, developing strategies for sustainable value creation, implementing and monitoring effective internal control systems ensuring relevant
- Prev
- 1
- Next